Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.
about
Advances in antibiotic therapy in the critically illClinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot StudyAntibiotic stewardship in the intensive care unit.Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort studyAn evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.High-dose continuous oxacillin infusion results in achievement of pharmacokinetics targets in critically ill patients with deep sternal wound infections following cardiac surgery.Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline.An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.Dose of colistin: a work in progress?A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics.Pro/con debate: continuous versus intermittent dialysis for acute kidney injury: a never-ending story yet approaching the finish?Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltrationAppropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenPharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy.Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?Pharmacokinetics of Peramivir in an Adolescent Patient Receiving Continuous Venovenous Hemodiafiltration.Aminoglycoside use in renal failure.Antibiotic dosing in critically ill patients with acute kidney injury.Drug absorption, distribution, metabolism and excretion considerations in critically ill adults.Phenytoin removal by continuous venovenous hemofiltration.Pharmacokinetic considerations for drugs administered in the critically ill.Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem.Dialyzability and pharmacokinetics of sitafloxacin following multiple oral dosing in infected hemodialysis patients.Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients.Antimicrobial Agents
P2860
Q26749328-872118B7-021E-4149-BAD4-87611604012AQ28551453-95D16E98-FD23-4B69-8A10-AE384BBF173CQ30408712-6CD6425A-B8F4-4D4F-997F-AAAE4DDD8309Q33654022-5D5C9346-D811-4E95-BF2D-51BC8AD5F4EFQ33751736-C0E2EAB6-AE82-462E-A9EA-5A91D5300BCAQ33982009-59C0FD7E-E43A-4696-9DC4-61C19F4F3EDBQ34057385-CCD59907-30AE-4C4F-82CA-EA8FA4635438Q34133346-A652D896-7E2B-4756-92AA-A9B4B726DDD5Q34470946-3B5606B6-E9B3-4572-9343-BB787BAC35ACQ35091624-78A81811-488A-4604-8165-3B5DFF3D7F0FQ35504097-3116C423-F291-4A84-82FE-9E678611DB64Q35567092-003D1017-2690-41EB-919B-97165E89571CQ35598435-BB18552C-8132-4B03-87EE-4FCE4F62A019Q36070363-B5B742BD-EA27-46EF-B40A-4CBF84B37610Q36322918-54EBBC7D-1B74-4814-A1E5-6A923E8D5A12Q37036404-B13835C8-DDE1-42C2-B2C8-3E62E2B735CEQ37119964-AF2F426C-4F12-469B-BB8D-92566FC65706Q37461431-785EB8A4-5096-458F-ABFF-B0AE7DFE253AQ37516599-8BDC16DC-A275-464B-A741-672338F5EFEDQ37686604-19EDBC54-B79C-4F68-AE56-2E15778BD227Q37808935-01614214-0A2F-4F87-8645-D0A78C3A565BQ37846092-11D87403-9F48-4099-A920-5B3D5E7BD302Q38107537-A22A1EB9-5A8F-4F98-87D2-852883A02E52Q38164694-C11FC544-B36C-48B5-A254-6CD8ABE32093Q38351793-D2BBDA08-10CB-4A04-A796-877602CC7581Q38382954-91BE7053-8D93-46B7-A70F-7184FC6EF2F2Q38790740-C8D3DAAD-604F-41E8-9176-828253FB89BBQ38833630-83EEDD31-EB34-4AF3-8F27-B937C949DCF2Q39074109-0CA241D0-FED1-4EE4-BAD2-77ED897DD265Q39936905-961A5AD6-2E76-437C-BC90-89C6591B790AQ40546653-3FFDA220-9617-4911-A3E6-C88C7DC1F02EQ42257467-3CB295B0-95E1-4E13-BCC3-FCF9D4533A89Q42706267-10364C26-AA91-4721-A069-71ED54A339ECQ44225880-1047B932-61A0-4616-8D9D-3405AD12ADF0Q49894608-F25F394C-60C5-48AD-8D31-5470E009B66AQ57549163-7D39E942-1649-4943-9A7D-7EBC001DE6EC
P2860
Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetic considerations ...... ing renal replacement therapy.
@en
Pharmacokinetic considerations ...... ing renal replacement therapy.
@nl
type
label
Pharmacokinetic considerations ...... ing renal replacement therapy.
@en
Pharmacokinetic considerations ...... ing renal replacement therapy.
@nl
prefLabel
Pharmacokinetic considerations ...... ing renal replacement therapy.
@en
Pharmacokinetic considerations ...... ing renal replacement therapy.
@nl
P2093
P2860
P1476
Pharmacokinetic considerations ...... ing renal replacement therapy.
@en
P2093
Federica Pavan
Federico Pea
Mario Furlanut
Pierluigi Viale
P2860
P304
P356
10.2165/00003088-200746120-00003
P577
2007-01-01T00:00:00Z
P6179
1037046770